Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapynews2026-05-28T13:38:47+00:00May 28th, 2026|Endpoints News|
China gene editing startup YolTech raises $70M to move CRISPR therapies forwardnews2026-05-28T12:30:25+00:00May 28th, 2026|Endpoints News|
Waypoint Bio raises $20M to run three CAR-T trials in Chinanews2026-05-27T10:45:29+00:00May 27th, 2026|Endpoints News|
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyoutnews2026-05-26T10:57:53+00:00May 26th, 2026|Endpoints News|
Fetal gene therapy’s progress calls into question the taboo on embryo editingnews2026-05-20T14:10:34+00:00May 20th, 2026|Endpoints News|
#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes livenews2026-05-15T10:45:33+00:00May 15th, 2026|Endpoints News|
Encoded’s gene therapy reduced seizures in Dravet syndromenews2026-05-14T18:50:34+00:00May 14th, 2026|Endpoints News|
ASGCT dispatch: In vivo CAR-T is everywherenews2026-05-14T18:24:17+00:00May 14th, 2026|Endpoints News|
Regenxbio hits Duchenne gene therapy milestone, eyes 2027 FDA approvalnews2026-05-14T11:00:17+00:00May 14th, 2026|Endpoints News|
After an apparent cure, a gene editing company struggles to repeat the magicnews2026-05-13T18:50:53+00:00May 13th, 2026|Endpoints News|
